TI
CHRS icon

Trexquant Investment’s Coherus Oncology CHRS Stock Holding History

Trexquant Investment’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-23,204
Closed -$223K – 1403
2022
Q3 		$223K Sell
23,204
-9,143
-28% -$92.5K 0.01% 1151
2022
Q2 		$234K Sell
32,347
-7,329
-18% -$63.7K 0.01% 1265
2022
Q1 		$512K Buy
39,676
+22,272
+128% +$283K 0.02% 763
2021
Q4 		$278K Buy
+17,404
New +$304K 0.02% 965
2021
Q2 		– Sell
-32,947
Closed -$481K – 1132
2021
Q1 		$481K Buy
+32,947
New +$559K 0.04% 526
2020
Q3 		– Sell
-19,152
Closed -$342K – 1224
2020
Q2 		$342K Buy
+19,152
New +$324K 0.02% 815
2019
Q3 		– Sell
-25,213
Closed -$557K – 887
2019
Q2 		$557K Buy
25,213
+3,977
+19% +$69.1K 0.05% 444
2019
Q1 		$290K Buy
+21,236
New +$283K 0.02% 758
2018
Q4 		– Sell
-71,266
Closed -$1.18M – 1058
2018
Q3 		$1.18M Buy
71,266
+59,016
+482% +$1.05M 0.09% 315
2018
Q2 		$172K Sell
12,250
-23,002
-65% -$329K 0.01% 806
2018
Q1 		$390K Buy
+35,252
New +$386K 0.03% 716
2017
Q2 		– Sell
-15,061
Closed -$319K – 825
2017
Q1 		$319K Buy
+15,061
New +$370K 0.04% 727
2016
Q4 		– Sell
-21,421
Closed -$574K – 970
2016
Q3 		$574K Buy
21,421
+1,382
+7% +$37.7K 0.13% 268
2016
Q2 		$338K Buy
+20,039
New +$376K 0.04% 626
2015
Q4 		– Sell
-38,400
Closed -$769K – 1039
2015
Q3 		$769K Buy
+38,400
New +$1.17M 0.07% 536

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Trexquant Investment's CHRS Position: Q4 2022 in Review

Trexquant Investment sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 23,204 shares — an estimated $223K sold.

Trexquant Investment first reported a position in CHRS in Q3 2015 and held it in 15 quarters. The position peaked at $1.18M in Q3 2018. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Trexquant Investment reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Trexquant Investment sold 23,204 Coherus Oncology shares in Q4 2022, an estimated $223K.
  • Trexquant Investment first reported a position in Coherus Oncology in Q3 2015 and held it in 15 quarters.
  • Trexquant Investment's Coherus Oncology position peaked at $1.18M in Q3 2018.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Trexquant Investment's 13F filing for Q4 2022, filed 13 Feb 2023.